Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts?
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright analyst Andres Y. Maldonado maintains $Scholar Rock(SRRK.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 46.
Scholar Rock Provides Preclinical Data for Its Investigational Obesity Candidate
Express News | Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist
Express News | Scholar Rock Holding Corp: First Participants Were Dosed in Phase 2 Embraze Proof-of-Concept Trial
Express News | Scholar Rock Announces New Srk-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Have Insiders Sold Scholar Rock Holding Shares Recently?
Investors may wish to note that the CFO, COO & Treasurer of Scholar Rock Holding Corporation, Edward Myles, recently netted US$85k from selling stock, receiving an average price of US$8.98. It migh
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $31
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and adjusts the target price from $29 to $31.According to TipRanks data, the analyst has a success rate of 58.7% a
Express News | Scholar Rock Holding Corp : BMO Raises Target Price to $31 From $29
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $29
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 58.7% and a to
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Scholar Rock(SRRK.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5%
Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors
Scholar Rock (SRRK) late Monday reported "encouraging" data from a phase 1 proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors. The company said
12 Health Care Stocks Moving In Monday's After-Market Session
GainersFibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ
Express News | Scholar Rock Holding Corp - Promising Objective Response Rates (Orr) Were Observed in Multiple Tumor Types in Anti-Pd-(L)1 Resistant Patients
Express News | Scholar Rock Holding Corp - Srk-181 Combination With Pembrolizumab Was Generally Well Tolerated
Express News | Scholar Rock Presents New Data From Srk-181 Phase 1 Dragon Trial at Asco 2024 Annual Meeting
Scholar Rock to Present New Data From SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago.
A Quick Look at Today's Ratings for Scholar Rock(SRRK.US), With a Forecast Between $28 to $30
On May 23, major Wall Street analysts update their ratings for $Scholar Rock(SRRK.US)$, with price targets ranging from $28 to $30.TD Cowen analyst Marc Frahm maintains with a buy rating.BMO Capital a